[Federal Register Volume 59, Number 227 (Monday, November 28, 1994)]
[Unknown Section]
[Page ]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-29133]
[Federal Register: November 28, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
National Technical Information Service
Prospective Grant of Exclusive Patent License
This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i) that the National Technical Information Service (NTIS),
U.S. Department of Commerce, is contemplating the grant of an exclusive
license in the United States of America to practice the inventions
embodied in the following series of U.S. Patents: 4,127,528, 4,127,518,
4,127,535, 4,127,534, 4,127,531, 4,127,532, 4,127,533, 4,139,504,
4,127,541, 4,127,523, 4,127,524, 4,127,525, 4,127,526, 4,127,527,
4,127,519, 4,127,520, 4,127,529, 4,127,530, 4,127,517, 4,127,536,
4,127,537, 4,127,538, 4,127,539, 4,127,540, 4,127,521, 4,127,522,
4,180,501, 4,213,968, and 4,312,857, to Trans-Neuro, Inc., having a
place of business in Wilmette, Illinois. The patent rights in these
inventions have been assigned to the United States of America.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
While the primary purpose of this notice is to announce NTIS' intent to
grant an exclusive license to practice the noted patents, it also
serves to publish said patents' availability for licensing in
accordance with law. The prospective exclusive license may be granted
unless, within 90 days from the date of this published notice, NTIS
receives written evidence and argument which establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR 404.7.
The series of related inventions expressed in the patents cited
above describe various peptides, endorphins and enkephalins believed to
be beneficial in the therapeutic treatment of a range of conditions
believed to be caused by defective brain mechanisms, including various
forms of mental illness.
Copies of the instant patents are available from the Commissioner
of Patents and Trademarks, Box 9, Washington, DC at a cost of $3.00
each.
Any inquiries and comments relating to the contemplated license
must be submitted to Neil L. Mark, Office of Federal Patent Licensing,
NTIS, Box 1423, Springfield, Virginia 22151. Properly filed competing
license applications received by the NTIS in response to this notice
will be considered as objections to the grant of the contemplated
license.
Douglas J. Campion,
Director, Office of Federal Patent Licensing.
[FR Doc. 94-29133 Filed 11-25-94; 8:45 am]
BILLING CODE 3510-04-M
